Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
2
|
| gptkbp:bfsParent |
gptkb:physicist
|
| gptkbp:acquisition |
gptkb:Medi_Wound_USA,_Inc.
|
| gptkbp:ceo |
Gal Cohen
|
| gptkbp:clinical_trial |
Phase 3 trials
|
| gptkbp:collaborations |
academic institutions
|
| gptkbp:focus |
wound care
|
| gptkbp:founded |
gptkb:2001
|
| gptkbp:headquarters |
gptkb:Yavne,_Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Medi Wound Ltd.
|
| gptkbp:investment |
Venture capital firms
|
| gptkbp:partnership |
gptkb:Medi_Wound_USA,_Inc.
|
| gptkbp:products |
gptkb:Nexo_Brid
gptkb:hospital gptkb:drug Eschar Ex |
| gptkbp:regulatory_compliance |
EMA approval for Nexo Brid
FDA approval for Nexo Brid |
| gptkbp:research_focus |
biologics for wound healing
|
| gptkbp:symbol |
MDWD
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.mediwound.com
|